Experimental studyOther modelOxidant and Antioxidant Activity in Rabbit Livers Treated With Zoledronic Acid
Section snippets
Material and Methods
The chemical structure of ZA (Sigma Cas. No. 118072-93-8) is designated as (1-hydroxyl-2-imidazole-1-yl-phosphonoethyl) phosphonic acid monohydrate; its chemical formula is C5H10N2O7P2 · H2O with molecular weight of 290.1 g/mol (Fig 1). ZA is available as a white crystalline powder that is reconstituted for injection with 5 mL of sterile water (USP) to be diluted in 100 mL of 0.9% sodium chloride (USP) or of 5% dextrose (USP) for intravenous (IV) injection. Animal investigations were performed
Results
We observed that GSH levels were significantly decreased in the ZA (1.7 ± 0.3) compared with the control group (2.5 ± 0.2). NO and MDA levels were significantly increased in the ZA group (24.4 ± 2.5 and 99.9 ± 28; both P < .0001) compared with controls (11.9 ± 1.5 and 43.5 ± 5.5; respectively; Table 1). The histopathological changes between the groups were not significantly different.
Discussion
ZA is a third-generation nitrogen-containing parenteral bisphosphonate indicated for the treatment of bone metastases due to solid tumors or multiple myeloma, for the hypercalcemia of malignancy, and for prevention of posttransplant bone fractures.10, 15 Their selective action on osteoclasts is due to effective endocytosis of bisphosphonates. The metabolites inhibit bone resorption by inducing osteoclast apoptosis, likely due to inhibition of ATP-dependent enzymes.16 The inhibition of
References (18)
- et al.
Bisphosphonates are effective prophylactic of early bone loss after renal transplantation
Transplant Proc
(2006) - et al.
Prophylactic bisphosphonate treatment prevents bone fractures after liver transplantation
Am J Transplant
(2007) - et al.
Determination of malonaldehyde precursor in tissues by thiobarbituric acid test
Anal Biochem
(1978) - et al.
Melatonin ameliorates tacrolimus (FK-506)'s induced immunosupressive effect in rat liver
Transplant Proc
(2009) - et al.
American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancerAmerican Society of Clinical Oncology Bisphosphonates Expert Panel
J Clin Oncol
(2000) - et al.
Zoledronic acid reduces skeletal-related events in patients with osteolylic metastases
Cancer
(2001) - et al.
Short-term effects of high-dose zoledronic acid treatment on bone mineralization density distribution after orthotopic liver transplantation
Calcif Tissue Int
(2008) - et al.
Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial
Ann Intern Med
(2006) - et al.
Bone metastasis in hepatocellular carcinoma: need for reappraisal of treatment
J Cancer Res Ther
(2008)